Comparative Safety of Second-Generation Antipsychotics and Risk of Pneumonia


Tue, Jun 25 11:45AM
T 32


Comparative Safety of Second-Generation Antipsychotics and Risk of Pneumonia

Abstract Summary

Study Design: This population based retrospective cohort study was conducted using a large nationally representative administrative claims database (2005-2011). Setting: The study population included elderly patients (65 years and older) taking atypical antipsychotic agents. Patients were included in the cohort if they were new users (no fill of atypical antipsychotics in the first six months of the study period) of atypical antipsychotic agents and continuously enrolled with medical and pharmacy benefits for six months before the initiation of antipsychotic treatment. Exposures: The atypical antipsychotics treatment exposure was measured using prescription claims data. The individual atypical antipsychotics studied were olanzapine, risperidone, quetiapine, ziprasidone, and aripiprazole. Outcome Measure: Risk of fatal or nonfatal diagnosis of pneumonia was examined based on ICD-9 CM codes. Statistical Analysis: The multiple propensity-score adjusted Cox proportional hazard model was used to examine risk of pneumonia within one year of follow up period. The patients were censored at the time of event (diagnosis of pneumonia), when they were switched to any other antipsychotic agents, or at death, disenrollment within one year, or reached the end of the study period.

Poster Presenter

Sandhya Mehta
PhD, MS,
Health Science Researcher,
Inovalon, Inc.
United States

© 2018 DIA